🔎 Trials Near Me

Domov › Akutna mieločna levkemija › Texas › Dallas

Klinične študije za Akutna mieločna levkemija v Dallas, TX

21 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Dallas in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 1
  • Children's Medical Center Dallas /ID# 275930, Dallas
6 Months – 17 Years · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07306832

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Baylor University Medical Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06852222

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03874052

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Vključevanje udeležencevFaza 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Vključevanje udeležencevFaza 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Starost 1–25 · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Vključevanje udeležencevFaza 1/2
  • Baylor Scott & White Health, Dallas
Starost 12 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Vključevanje udeležencevFaza 3
  • US-Dallas TX-SOUTHWESTERN, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Vključevanje udeležencevFaza 1/2
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Do 22 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Harold C. Simmons Comprehensive Cancer Center, Dallas
29 Days – 21 Years · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Vključevanje udeležencevFaza 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 20. avg. 2026 · NCT06001788

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • UT Southwestern/Simmons Cancer Center, Dallas
Starost 1–30 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06177067

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Vključevanje udeležencevFaza 3
  • Baylor Charles A. Sammons Cancer Center, Dallas
Starost 18–75 · Vsi spoli · Posodobljeno 17. jul. 2026 · NCT05429632

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT04659616

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Vključevanje udeležencevOpazovalna študija
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Vse starosti · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT01351545

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Vključevanje udeležencevFaza 2
  • UT Southwestern Medical Center at Dallas, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 23. jun. 2026 · NCT05401097

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Vključevanje udeležencevFaza 1
  • UT Southwestern Medical Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT02074839

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • Baylor University Medical Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT05768932

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Vključevanje udeležencevFaza 2/3
  • University of Texas Southwestern Medical Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 30. apr. 2026 · NCT04256317

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Vključevanje udeležencevFaza 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 13. mar. 2026 · NCT05735184

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Vključevanje udeležencevFaza 1
  • University of Texas Southwestern Medical Center, Dallas
Starost 18 in več · Vsi spoli · Posodobljeno 11. maj 2025 · NCT06634394

Študije za Akutna mieločna levkemija v drugih mestih

Druge študije v Dallas

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.